Cargando…
An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning
Metabolic syndrome (MetS) is a clustering of several cardiovascular risk factors that include: obesity, dyslipidemia, hypertension and high blood glucose, and often requires multidrug pharmacological interventions. The management of MetS therefore requires high healthcare cost, and can result in poo...
Autores principales: | Rameshrad, Maryam, Razavi, Bibi Marjan, Lalau, Jean-Daniel, De Broe, Marc E., Hosseinzadeh, Hossein |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mashhad University of Medical Sciences
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374997/ https://www.ncbi.nlm.nih.gov/pubmed/32742592 http://dx.doi.org/10.22038/ijbms.2020.41638.9832 |
Ejemplares similares
-
Effect of safranal, a constituent of saffron, on olanzapine (an atypical antipsychotic) induced metabolic disorders in rat
por: Malekzadeh, Sara, et al.
Publicado: (2019) -
Evaluation of possible effects of crocin against nitrate tolerance and endothelial dysfunction
por: Omidkhoda, Seyedeh Farzaneh, et al.
Publicado: (2020) -
A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19)
por: Rameshrad, Maryam, et al.
Publicado: (2020) -
Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents
por: Mousa, Shaker A., et al.
Publicado: (2019) -
The effects of ginseng on the metabolic syndrome: An updated review
por: Aminifard, Tahereh, et al.
Publicado: (2021)